In August 2025, Dr. Jeng Her, Founder and CEO of AP Biosciences, was interviewed by PharmaBoardroom during the Evercore China Biotech Summit in Shanghai. We extend our heartfelt thanks to Dianna Viola, CEO of PharmaBoardroom, for arranging this engaging and insightful conversation, resulting in an exceptionally well-written feature.
In the interview, Jeng shared the journey of AP Biosciences since its founding in 2013 and the company's strategy to develop next-generation bispecific antibodies using its proprietary T-cube platform. The lead asset, AP203, is currently in the Phase I clinical trial, showing early promise in colorectal and lung cancer. Jeng emphasized that the future of bispecific antibodies extends beyond oncology, with AP Biosciences aiming to lead globally in this field. He also highlighted Taiwan's biotech ecosystem, including its strong talent pool and supportive capital market, while addressing how the company navigates business development challenges to achieve steady growth.
Read the full interview here: PharmaBoardroom Website. We look forward to continuing our mission to deliver safer, more effective therapies for patients worldwide!
